人工周期冻融胚胎移植改善妊娠中晚期子宫灌注但子痫前期发生率更高
该回顾性单中心研究纳入27495例单胎妊娠,分析不同受孕方式对妊娠中晚期子宫动脉搏动指数的影响。结果显示人工周期冻融胚胎移植在中晚孕期子宫动脉搏动指数均显著低于其他受孕方式,提示子宫血管阻力降低、灌注改善。但人工周期冻融胚胎移植的子痫前期发生率为5.2%,约为自然周期冻融胚胎移植的4倍,提示需修订现行子痫前期风险评估流程。
要点
- 人工周期冻融胚胎移植妊娠中晚期子宫动脉搏动指数显著低于其他受孕方式,提示子宫灌注改善。
- 人工周期冻融胚胎移植子痫前期发生率为5.2%,高于自然周期冻融胚胎移植的1.1%。
- 基于子宫动脉搏动指数的现行子痫前期风险评估流程可能需针对人工周期冻融胚胎移植妊娠进行调整。
核心结论
- 人工周期冻融胚胎移植与妊娠各孕期子宫血管阻力降低相关。
- 尽管子宫灌注改善,人工周期冻融胚胎移植的子痫前期发生率显著高于其他受孕方式。
- 研究结果支持迫切需要修订现行中晚孕期子痫前期风险评估流程,以确保高危妊娠的早期识别和恰当管理。
研究设计与样本
- 回顾性单中心研究,纳入2010年1月至2024年11月期间27495例单胎妊娠,均在孕20-22周完成子宫动脉搏动指数评估。
- 其中23547例为自然受孕,3948例为辅助生殖技术妊娠,包含2699例冻融胚胎移植,其中2343例为人工周期、356例为自然周期方案。
- 11096例妊娠有孕35-37周子宫动脉搏动指数数据,排除了胎儿先天异常、非整倍体和双胎妊娠。
- 采用协方差分析和线性混合模型进行分析,校正吸烟、糖尿病、种族、慢性高血压、阿司匹林使用、血栓性疾病、年龄、体重和卵母细胞捐献等混杂因素。
主要发现
- 人工周期冻融胚胎移植孕20-22周子宫动脉搏动指数为0.73,显著低于自然受孕的0.89、促排卵联合宫腔内人工授精的0.92、新鲜胚胎移植的0.94和自然周期冻融胚胎移植的0.89,P<.001。
- 差异在孕35-37周持续存在,人工周期冻融胚胎移植子宫动脉搏动指数为0.95,低于自然受孕的1.00、促排卵联合宫腔内人工授精的1.03、体外受精冻融胚胎移植的1.00和自然周期冻融胚胎移植的1.02,P<.001。
- 多变量回归分析后上述结果仍然成立。
- 人工周期冻融胚胎移植子痫前期发生率为5.2%,高于自然周期冻融胚胎移植的1.1%、自然受孕的1.4%、促排卵联合宫腔内人工授精的1%和新鲜胚胎移植的2.2%,P<.001。
关键数值与推荐
- 孕20-22周子宫动脉搏动指数为0.73对应人工周期冻融胚胎移植,0.89对应自然受孕,0.92对应促排卵联合宫腔内人工授精,0.94对应新鲜胚胎移植,0.89对应自然周期冻融胚胎移植。
- 孕35-37周子宫动脉搏动指数为0.95对应人工周期冻融胚胎移植,1.00对应自然受孕,1.03对应促排卵联合宫腔内人工授精,1.00对应体外受精冻融胚胎移植,1.02对应自然周期冻融胚胎移植。
- 子痫前期发生率:人工周期冻融胚胎移植5.2%、自然周期冻融胚胎移植1.1%、自然受孕1.4%、促排卵联合宫腔内人工授精1%、新鲜胚胎移植2.2%。
临床怎么用
- 对人工周期冻融胚胎移植妊娠患者,临床不应因中晚孕期子宫动脉搏动指数较低而放松对子痫前期的警惕。
- 对人工周期冻融胚胎移植妊娠的个体,可能应采用不同于自然受孕妊娠的子痫前期风险评估策略。
- 现行以子宫动脉搏动指数为依据的中晚孕期子痫前期风险筛查方案在人工周期冻融胚胎移植妊娠中可能低估风险。
局限性
- 该研究为回顾性单中心设计,可能存在选择偏倚和残余混杂。
- 研究未提供不同受孕方式间母体基础特征及子痫前期其他危险因素分布的完整比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Uterine artery pulsatility index is a key biomarker for preeclampsia screening and the most reliable indicator of uterine perfusion across all pregnancy trimesters. Although recent findings reveal a significant decrease in uterine artery pulsatility index during first trimester in artificial cycle frozen embryo transfer pregnancies, no previous study evaluated whether this decrease persists throughout the second and third trimesters, when hormonal treatment is discontinued. Considering the crucial role of uterine artery pulsatility index during the second half of pregnancy risk assessment, recommended by international guidelines to ensure early preeclampsia detection and proper pregnancy monitoring, we set out to perform a large retrospective study to evaluate the impact of endometrial preparation on second and third trimesters uterine artery pulsatility index. OBJECTIVE: The study aims to evaluate the possible impact of endometrial preparation for frozen embryo transfer on uterine vascular resistance during the second and third trimesters. STUDY DESIGN: This retrospective single-center study analyzed 27,495 singleton pregnancies that underwent Uterine Artery Pulsatility Index evaluation during the second trimester (20-22 weeks) of pregnancy at our University Hospital between January 2010 and November 2024. Among them, 23,547 were naturally conceived and 3948 resulted from Assisted Reproductive Technology (385 ovulation induction and intrauterine insemination, 864 in vitro fertilization frozen embryo transfer, and 2699 after frozen embryo transfer) (356 natural cycle frozen embryo transfer and 2343 artificial cycle frozen embryo transfer). Additionally, third trimester (35-37 weeks) Uterine Artery Pulsatility Index evaluations were available for 11,096 pregnancies. Pregnancies with fetal congenital abnormalities, aneuploidies, and twin pregnancies were excluded. The primary aim of the study was to investigate Uterine Artery Pulsatility Index values throughout pregnancy based on different types of conception. Analysis of covariance and linear mixed model (including potential confounders such as smoking, diabetes, race, chronic hypertension, aspirin administration, thrombophilia, age, weight, and oocyte donation) were used to analyze the association between mode of conception and log10-transformed multiple of the median values of Uterine Artery Pulsatility Index. RESULTS: The use of hormonal treatment in artificial cycle frozen embryo transfer cycles was associated with a significantly lower second-trimester Uterine Artery Pulsatility Index values 0.73 (artificial cycle frozen embryo transfer) as compared with all other modes of conception vs 0.89 (naturally conceived), 0.92 (ovulation induction and intrauterine insemination), 0.94 (fresh embryo transfer), and 0.89 (natural cycle frozen embryo transfer) (P<.001). Differences persisted during the third trimester with Uterine Artery Pulsatility Index values 0.95 for artificial cycle frozen embryo transfer vs 1.00 (naturally conceived), 1.03 (ovulation induction and intrauterine insemination), 1.00 (in vitro fertilization frozen embryo transfer), and 1.02 (natural cycle frozen embryo transfer) (P<.001). The results were confirmed after applying the multivariable regression analysis. Despite the improved uterine perfusion, artificial cycle frozen embryo transfer was associated with a 4-fold higher incidence of preeclampsia (5.2%) compared to natural cycle frozen embryo transfer (1.1%), naturally conceived (1.4%), ovulation induction and intrauterine insemination (1%), and fresh embryo transfer (2.2%) (P<.001). CONCLUSION: The present study demonstrates that artificial cycle frozen embryo transfer is associated with reduced uterine vascular resistance across all pregnancy trimesters. This finding strongly supports the urgent need to revise the current second and third trimester preeclampsia risk assessment algorithm to ensure accurate early detection and proper management of high-risk pregnancies.
引用
- Donno, Prats, Plancha, et al. Artificial cycle frozen embryo transfer improves uterine perfusion during later pregnancy but is associated with higher preeclampsia incidence. Am J Obstet Gynecol. 2026. PMID: 41730489. doi:10.1016/j.ajog.2026.02.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。